Introduction
============

X-linked adrenoleukodystrophy (X-ALD; Online Mendelian Inheritance in Man no. 300100) is the most common type of inherited peroxisomal disorder and monogenic leukodystrophy that occurs in \~1 in 17,000 live male births with no apparent difference in the prevalence among different ethnicities ([@b1-etm-0-0-7804]). The clinical manifestation is highly variable, including progressive demyelination of the central and peripheral nervous systems, adrenal insufficiency, and accumulation of very long chain fatty acids (VLCFAs) in body fluid and tissues ([@b2-etm-0-0-7804]). Adrenomyeloneuropathy (AMN) and the cerebral form of X-ALD (CALD) are the two most common phenotypes of X-ALD. CALD includes the childhood (CCALD), adolescent (AdolCALD) and adult forms with onset ages of 3--10, 11--20 and \>21 years, respectively ([@b3-etm-0-0-7804],[@b4-etm-0-0-7804]). CCALD, the most fatal phenotype, is associated with rapidly progressive inflammatory brain demyelination and frequently leads to total disability within 3 years.

X-ALD is caused by mutations in the ATP-binding cassette protein subfamily D1 (ABCD1; GenBank accession no., NM_000033) gene, which is located on the X chromosome at Xq28 ([@b5-etm-0-0-7804]). The gene contains 10 exons and encodes the ALD protein (ALDP), which is located in the peroxisome membrane and has an important role in transporting VLCFAs from the cytosol into the peroxisome for degradation ([@b6-etm-0-0-7804]). Functional defects of ALDP block this transport, resulting in impaired degradation of VLCFAs and subsequent accumulation of VLCFAs in cells, tissues and organs, mainly in the white matter and axons of the central nervous system and the adrenal glands ([@b7-etm-0-0-7804]). The accumulation of VLCFAs has a toxic effect by evoking mitochondrial dysfunction and by causing the breakdown of cell membranes as a result of oxidative stress. The molecular mechanisms associated with the pathogenesis of X-ALD are summarized in [Fig. 1](#f1-etm-0-0-7804){ref-type="fig"}. To date, \~2,692 mutations in the ABCD1 gene have been reported and recorded in the ALD database (<https://adrenoleukodystrophy.info/>). Mutation analysis of the ABCD1 gene is of great value to make a definite diagnosis and provide genetic counseling to families ([@b8-etm-0-0-7804],[@b9-etm-0-0-7804]).

Various Chinese studies have reported on X-ALD ([@b10-etm-0-0-7804]--[@b13-etm-0-0-7804]); however, the rate of early identification and genetic diagnosis remain low. Identification of more novel mutations in the ABCD1 gene and investigation of clinical characteristics and phenotype distribution in the Chinese population may expand the current knowledge on X-ALD and ideally provide improved references for genomics-based treatments and prevention strategies. The present study performed a retrospective analysis of 10 Chinese patients with X-ALD diagnosed during infancy or adulthood and evaluated their long-term outcomes.

Materials and methods
=====================

### Patients

All patients were diagnosed with X-ALD at the Shandong Provincial Hospital Affiliated to Shandong University (Jinan, China) between July 1994 and June 2016. The diagnosis was based on neurological symptoms, including pyramidal symptoms, impaired hearing and language skills, behavioral changes, epilepsy, cognition impairment, inflammatory brain demyelination on brain magnetic resonance imaging (MRI), adrenal dysfunction, increased concentration of plasma VLCFA and gene mutation analysis ([@b14-etm-0-0-7804]).

### Clinical data analysis

Patient records in electronic format and on paper were reviewed for clinical features, biochemical parameters, diagnostic images, molecular genetic tests, treatments and long-term outcomes. The disease phenotype, including symptoms and laboratory results, were evaluated at the first presentation. Telephone consultation was also performed when required. The clinical characteristics of one of these patients have been previously reported ([@b15-etm-0-0-7804]). To facilitate the diagnosis of the patients, the plasma levels of adrenocorticotropic hormone (ACTH) and cortisol were determined by electrochemiluminescence immunoassay (Elecsys ACTH and Cortisol II, Roche Diagnostics). Plasma VLCFA levels were determined by gas chromatography/mass spectrometry (QP5050A; Shimadzu). Electromyography (EMG) and nerve conduction velocities (NVC) were measured using Keypoint Amplifier (cat. no. 9031C0762; Dantec Ltd.). Lumbar puncture was conducted by an experienced neurological physician and cerebrospinal fluid (CSF) analyses were performed routinely.

### Mutation analysis of the ABCD1 gene

Genomic DNA was prepared from peripheral blood leukocytes sampled from the patients using a genomic DNA extraction kit (QIAamp Blood DNA Mini kit; Qiagen). Previously published primer sequences and amplifying conditions were used to amplify the whole ABCD1 gene ([@b6-etm-0-0-7804]). The complete coding sequence and all of the exon-intron boundaries of the ABCD1 gene were subjected to automated sequencing on an ABI 3500 DNA sequencer (Thermo Fisher Scientific, Inc.). The analyzed sequences were compared to the corresponding wild-type sequences of ABCD1 in GenBank (NM_000033). Direct sequencing of the ABCD1 gene from 100 control samples (age, 38.7±9.3 years; male/female ratio, 1.2:1.0) was also performed to rule out any polymorphisms. All of the controls were recruited from the examination center of Shandong Provincial Hospital (Jinan, China) from April 2015 to September 2015. All subjects provided written informed consent for the collection and use of their blood samples for the purposes of research and for the publication of their results.

### Follow-up examinations

Follow-up examinations were approved by the ethics committee. All patients were reviewed by telephone every six months following the first diagnosis. Patients were seen at our hospital for examination and treatment once every year or if there were any special circumstances, such as 2 patients who had communication problems. The symptoms, treatments, occurrence of potential complications and the evolution of the disease were closely monitored.

### Statistical analysis

Data were analyzed using SPSS v.17.0 (SPSS, Inc., Chicago, IL, USA). Values are expressed as the median (range) or the mean ± standard deviation. Differences between means were compared using one-way analysis of variance for multiple comparisons and Dunnett\'s test was performed as a post-hoc test. All of the calculated P-values were two-sided and P\<0.05 was considered to indicate a statistically significant difference.

Results
=======

### Clinical characteristics and phenotypes

A total of 10 patients (all males) were included in the present retrospective study. They were all offspring of non-consanguineous marriages and were born after an uneventful full-term pregnancy. The median age at onset of disease was 8.2 years old (range, 3--29 years). According to the clinical symptoms of different phenotypes described previously ([@b2-etm-0-0-7804],[@b3-etm-0-0-7804]), most of the patients had CCALD at an age of 3--10 years (n=8) and 1 patient had AdolCALD (age, 12 years old). Of note, one 29-year old patient had adult-onset olivo-ponto-cerebellar X-ALD, a rare form of X-ALD (prevalence, 1--2% of X-ALD) with clinical features of cerebellar and brainstem involvement in adolescence or adulthood ([@b4-etm-0-0-7804]). The mean duration of follow-up was 9.05±5.20 years. The phenotypes, clinical features, family history and adrenal dysfunction of the patients are summarized in [Table I](#tI-etm-0-0-7804){ref-type="table"}. Paraclinical and laboratory studies were performed and the results are summarized in [Table II](#tII-etm-0-0-7804){ref-type="table"}.

Two of the patients have a family history of X-ALD or Addison\'s disease (20%). Most of the family members refused any clinical genetic investigations thus far; however, a certain number of carriers in the respective families would be expected. All patients were symptomatic at the time of the diagnosis, and none of them was diagnosed in the asymptomatic stage based on a positive family history of X-ALD. Most patients (8/10) had the manifestation of adrenal dysfunction characterized as hyperpigmentation in lips, gums and even the whole body owing to high levels of ACTH. Neurodevelopmental regression and behavioral problems were common. The clinical manifestations included visual impairment (n=4), unsteady gait (n=3), memory decline (n=2), impaired language skills (n=2) and cognitive decline (n=3).

### Brain images

The brain images of all patients exhibited abnormalities. T2-weighted hyperintensity (caused by neurocyte demyelination) on MRI was observed in the cerebrum of 5 patients, and 6 patients had lesions in the brainstem, internal capsule and/or cerebellum. The initial abnormalities usually start from the splenium of the corpus callosum and then spread into the adjacent white matter of the parieto-occipital lobes ([@b13-etm-0-0-7804]). The MRI of 1 patient was not available; however, his cerebral CT exhibited diffuse atrophy and diffuse hypodensities in the white matter and posterior horn of the lateral ventricles and centrum semiovale. All of the cerebral demyelinating lesions were symmetric. The most severe demyelination (case no. 10) is presented in [Fig. 2](#f2-etm-0-0-7804){ref-type="fig"}. These images showcase the characteristics on MRI for the diagnosis of the disorder. Of note, MRI is currently used in China to monitor young males who have a high risk of developing cerebral X-ALD ([@b16-etm-0-0-7804]).

### Biochemical analysis

Plasma hexacosanoic acid (C26:0) levels were determined at the time of diagnosis. VLCFA analysis revealed high plasma levels of C26:0 in all patients. The median (range) levels of C26:0 were 2.92 (1.51--4.22) nmol/ml (normal, ≤1.3 nmol/ml). There was no significant difference in the elevated VLCFA levels among patients with different phenotypes of X-ALD (P\>0.05).

At the time of the first presentation at our hospital, none of the patients had previously received hydrocortisone therapy. High levels of ACTH and low levels of cortisol (measured at 8 am and at 4 pm) were present in half of the patients, which were indicative of a state of adrenocortical insufficiency.

### Paraclinical and laboratory results

Of the 10 patients, 8 were subjected to neurophysiological examination, of whom 5 patients presented with an aberration on EMG and/or in NVC, which included moderate sensorimotor peripheral neuropathy in the extremities with predominantly axonal changes. There was no association between neurophysiological results and the severity of the symptomatic status. Other electrophysiological examinations, including electrocardiogram, visual evoked potentials, brainstem auditory evoked potentials and somatosensory evoked potentials, were in the normal ranges (data not shown).

CSF analyses were mostly normal; two out of 10 patients presented with slightly elevated CSF protein levels above the normal range.

### Mutations in the ABCD1 gene

A total of 3 different mutations were identified in 3 patients, including 2 missense mutations (p.V583E, p.S149R) and 1 nonsense mutation (p.W601\*). The p.S149R mutation has been identified in the same patient, which has already been reported in a previous study by our group ([@b14-etm-0-0-7804]), and this mutation was likely to be pathogenic based on the *in silico* analysis prediction tools and elevated level of VLCFA. The other two mutations were also described previously ([@b17-etm-0-0-7804]). The remaining 7 patients denied genetic testing.

### Therapy and follow-up

[Table III](#tIII-etm-0-0-7804){ref-type="table"} summarizes the therapy and follow-up of patients with X-ALD. During hospitalization, most patients received neurotrophic drugs, and if adrenal insufficiency was present, hydrocortisone replacement therapy was initiated. All of the patients were requested to follow a low-VLCFA diet. Occasionally, medical therapies were provided with supportive care by rehabilitation physicians.

During follow-up, X-ALD phenotypes progressed with time. With time, almost all of the patients are at risk of developing neurologic (CALD, AMN) or endocrinologic (Addison\'s disease) symptoms. In most of these patients (6/10), chronic myelopathy and peripheral neuropathy progressed with time, gradually leading to a vegetative state or paralysis within several years of clinical symptom onset. Case no. 8 received a hematopoietic stem cell transplantation (HSCT) at the advanced stage of the disease. He exhibited neurological improvement for 3 months post-transplantation. However, after another 3 months, his symptoms gradually deteriorated with progressive mental disorder and he died 1 year after the transplantation.

Discussion
==========

In the present study, the clinical data of 10 Chinese patients with X-ALD were retrospectively reviewed and a follow-up study was performed. Most of the patients (8/10) had CCALD. One patient presented with the olivo-ponto-cerebellar form, the rarest form of ALD. The brain MRIs of all patients exhibited abnormalities with typical T2-weighed hyperintensity. VLCFA analysis revealed high plasma levels of C26:0 in all patients. Increased ACTH, decreased cortisol and neurophysiological manifestations were also noted. In 3 of the patients, 3 different mutations of the ABCD1 gene were identified. During follow-up, most patients took neurotrophic drugs and received hydrocortisone replacement when required. Furthermore, one patient received HSCT. The present results may enhance the current understanding of this disorder and provide valuable information for the future prevention and therapies for this disorder.

Of note, one of the patients of the present study had the adult-onset olivo-ponto-cerebellar form, the rarest form of X-ALD, which is the same patient that has been previously described by our group ([@b14-etm-0-0-7804]). Approximately 88% of olivo-ponto-cerebellar X-ALD patients are from Korea and Japan ([@b18-etm-0-0-7804]). One case was reported in Taiwan ([@b19-etm-0-0-7804]). To the best of our knowledge, the present case was the first case from the Chinese mainland that was ever reported. Genetic analysis confirmed the diagnosis based on a mutation (c.447T\>A; p.S149R) in the ABCD1 gene detected in this patient. A further molecular functional study may provide more insight into the underlying mechanisms of this disease.

In agreement with a previous study from China, the majority of the CCALD cases were of CCALD (80%) ([@b20-etm-0-0-7804]). Almost all of these patients had adrenocortical insufficiency (Addison\'s disease), which may be the only clinical manifestation that was apparent prior to the onset of cerebral symptoms ([@b21-etm-0-0-7804],[@b22-etm-0-0-7804]). According to certain studies, adrenocortical insufficiency was the first symptom of X-ALD in 38% of patients ([@b23-etm-0-0-7804]), adrenal symptoms appeared prior to neurological symptoms in 92% of cases of CCALD ([@b24-etm-0-0-7804]) and the incidence was 100% in those patients whose adrenal insufficiency became evident prior to the age of 7.5 years ([@b25-etm-0-0-7804]). These results are clinically significant. In male patients presenting with Addison\'s disease, including those who only have a glucocorticoid deficiency, X-ALD should be taken into consideration, and plasma VLCFA levels should be determined ([@b14-etm-0-0-7804]). The requirement to investigate X-ALD and plasma VLCFA levels is particularly important in patients whose adrenal insufficiency manifested prior to the age of 7.5 years.

However, throughout the world, CCALD is not the most common phenotype of ALD ([@b26-etm-0-0-7804]). The fact that most studies from China report on a higher percentage of CCALD compared to other countries may be due to numerous patients with milder phenotypes remaining undiagnosed, particularly those with AMN, the most common phenotype ([@b4-etm-0-0-7804]). Therefore, a bias regarding the detection of phenotypes may exist in China.

In addition, X-ALD should be considered in young and adult males presenting with cognitive and neurological symptoms with white matter lesions on brain MRI. For females with X-ALD, mutation analysis of the ABCD1 gene should also be performed, as plasma VLCFA levels were reported to be normal in 15% of females with X-ALD ([@b3-etm-0-0-7804]). A more recent study revealed that females with X-ALD with normal plasma VLCFA levels had elevated C26:0-lysophosphatidylcholine (C26:0-lyso-PC) according to dried blood spot analysis ([@b27-etm-0-0-7804]). Analysis of C26:0-lyso-PC is cheaper than conventional plasma VLCFA analysis and may be performed using dried bloodspots, which are generated on Guthrie paper; they may be stored at room temperature and sent to diagnostic centers. Therefore, C26:0-lyso-PC analysis should be added to the routine biochemical array of diagnostic tests for peroxisomal disorders. Regarding the diagnosis, MRI was observed to be more sensitive than CT scan. MRI exhibited a larger area of abnormality, particularly when there was anincreased signal intensity on T2-weighted and fluid-attenuated inversion recovery sequences in the splenium of the corpus callosum and white matter of the parieto-occipital lobes ([@b28-etm-0-0-7804]).

Follow-up of patients with X-ALD is important for two reasons: i) Early detection of adrenocortical insufficiency and ii) early detection of CALD for the purpose of intervention by allogeneic HSCT ([@b25-etm-0-0-7804]). There are no unified guidelines for the management of X-ALD and to date, HSCT is considered to be the only effective approach to prevent the progression of cerebral demyelination in X-ALD ([@b29-etm-0-0-7804]). It is recommended to perform HSCT an early stage of the disease to accomplish a prolonged beneficial effect. Thus, it is required to diagnose X-ALD as early as possible, since treatment, including allogenic HSCT in the early stage ([@b29-etm-0-0-7804]) and endocrine replacement therapy for adrenocortical insufficiency, is applicable in certain cases. At present, there is no definitive cure for X-ALD. Pedigree studies, as well as identification of individuals at high risk, are required to establish an early preventive treatment plan involving genetic counseling and prevention of disease development in mutation carriers, to provide suitable professional advice for each individual patient.

X-ALD is an inherited peroxisomal disorder due to mutations in the ABCD1 gene ([@b2-etm-0-0-7804]). According to the ALD database, 2,692 different mutations in the ABCD1 gene have been detected thus far, of which 806 mutations (30%) appear to be nonrecurrent. Missense mutations, accounting for 61%, are the most common type among ABCD1 mutations. Other mutations include frameshift mutations (17%), nonsense mutations (10%), amino acid insertions or deletions (4%; [Fig. 3](#f3-etm-0-0-7804){ref-type="fig"}). The distribution of mutations is imbalanced. Of the mutations, \~50% occurred in exon 1, which encodes the transmembrane domain of the ABCD1 protein. Another clustering of mutations is in exons 6--9, which encode the ATP binding domain of ALDP ([@b3-etm-0-0-7804]). However, the spectrum of ABCD1 mutations may exhibit geographical distribution differences in different ethnicities. Genotype-phenotype association analyses have been performed ever since the X-ALD gene was identified in 1993. However, no genotype-phenotype correlation has been detected ([@b26-etm-0-0-7804],[@b30-etm-0-0-7804]).

The major limitation of the present study is the absence of screening for mutations in the remaining patients. Another limitation involved the communication difficulties during telephone interview because some of the patients had problems with their hearing, communication and perception. This may bring some bias on the description of the symptoms.

In conclusion, the present retrospective study of 10 Chinese patients with X-ALD suggests that it is critical to investigate X-ALD in male patients with adrenocortical insufficiency. Furthermore, it is essential to diagnose patients early, since treatment is available in certain cases. In a future study, more X-ALD patients will be recruited to establish a prospective study cohort. By performing follow-ups, the clinical characteristics, development and prognosis of the disease will be explored.
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![Schematic illustrating the molecular mechanisms associated with the pathogenesis of X-ALD. The mutated ABCD1 gene encodes a defective ALDP that blocks VLCFA transport to the peroxisome. This defective transport leads to the impaired degradation of VLCFAs and subsequent accumulation of VLCFA in mainly the white matter and axons of the central nervous system and the adrenal system. Subsequently, mitochondrial dysfunction evoked by oxidative stress, ER stress and lipid-induced cell death are caused by the accumulation of VLCFA. Finally, the nervous system and the adrenal cortex are primarily affected, leading to neurodegeneration and adrenocortical insufficiency. ABCD1, ATP binding cassette subfamily D member 1; ER, endoplasmic reticulum; ROS, reactive oxygen species; ALDP, adrenoleukodystrophy protein; VLCFA, very long chain fatty acid.](etm-18-03-1945-g00){#f1-etm-0-0-7804}

![Magnetic resonance images of the brain of Case no. 10 exhibiting characteristic extensive white matter changes. T1-weighted low-signal-intensity, T2-weighted high-signal-intensity and T2 FLAIR high-signal-intensity lesions (highlighted with red arrow) were present symmetrically in the bilateral white matter around the lateral ventricle, genu and splenium of the corpus callosum as well as in the cerebellum. The demyelinating lesions are extensive and correspond to an advanced disease stage. FLAIR, fluid-attenuated inversion recovery.](etm-18-03-1945-g01){#f2-etm-0-0-7804}

![Statistics of ABCD1 mutations (upper panel) and genomic structure of the human ABCD1 gene and incidence of mutations in each genomic amplicon (lower panel). ABCD1, ATP binding cassette subfamily D member 1.](etm-18-03-1945-g02){#f3-etm-0-0-7804}

###### 

Demographic data and clinical characteristics of 10 patients with X-ALD.

  Case no.   Age at onset (years)   Age at diagnosis (years)   Clinical features                                                                                         Family history   Adrenal dysfunction   Phenotype
  ---------- ---------------------- -------------------------- --------------------------------------------------------------------------------------------------------- ---------------- --------------------- ----------------------------
  1          3                      3                          Vomiting, skin pigmentation, pyramidal symptoms, adrenal crisis                                           −                \+                    CCALD
  2          4                      6                          Hearing impairment, walking instability after a head blow, skin pigmentation, pyramidal symptoms          −                \+                    CCALD
  3          4                      5                          Visual impairment, hearing impairment, hallucination of soliloquy, pyramidal symptoms                     \+               −                     CCALD
  4          7                      7                          Visual impairment, unsteady gait, memory decline, skin pigmentation, pyramidal symptoms, adrenal crisis   −                \+                    CCALD
  5          3                      3                          Convulsion, unsteady gait, aphasia, pyramidal symptoms                                                    −                −                     CCALD
  6          6                      7                          Visual impairment, easy to tumble down, skin pigmentation                                                 −                \+                    CCALD
  7          6                      6                          Convulsion after a head blow, skin pigmentation                                                           \+               \+                    CCALD
  8          8                      8                          Visual impairment, convulsion, memory decline, skin pigmentation, pyramidal symptoms                      −                \+                    CCALD
  9          12                     12                         Unsteady gait, impaired language skills, pyramidal symptoms                                               −                \+                    AdolCALD
  10         29                     30                         Ataxia, impaired language skills, difficult swallowing, skin pigmentation, pyramidal symptoms             −                \+                    Olivo-ponto-cerebellar ALD

All subjects were males. Adrenal dysfunction includes Addison\'s disease, hyperpigmentation, serum corticotropin level, serum cortisol level, abnormal result for rapid corticotropin test, urinary 17-ketosteroids and urinary 17-hydroxycorticosteroids. Pyramidal symptoms include hyperreflexia, Babinski sign, spastic paraplegia and/or spasticity. X-ALD, X-linked adrenoleukodystrophy; NA, not available; CALD, cerebral form ALD; CCALD, childhood CALD; ACALD, adulthood CALD; AdolCALD, adolescent CALD; +, positive; -, negative.

###### 

Paraclinical and laboratory studies of 10 patients with X-linked adrenoleukodystrophy.

       MRI T2WI high signal   Serum cortisol                                                                     
  ---- ---------------------- ---------------- --------------- ------------- -------- ------ -------------- ---- ----------
  1    \+                     −                1.5 µg/dl       0.9 µg/dl     \>2000   3.01   −              −    NA
  2    −                      \+               1.1 µg/dl       1.2 µg/dl     \>2000   2.67   −              \+   NA
  3    \+                     −                4.2 µg/dl       \<1.0 µg/dl   \>2000   2.88   −              −    NA
  4    \+                     \+               2.1 µg/dl       1.1 µg/dl     \>2000   1.72   Protein high   \+   NA
  5    NA (CT)                NA (CT)          5.0 µg/dl       6.0 µg/dl     354      1.64   Protein high   \+   p.V583E
  6    \+                     −                9.6 µg/dl       10.8 µg/dl    126      2.96   NA             −    NA
  7    −                      \+               10.65 nmol/l    NA            \>2000   3.43   NA             NA   NA
  8    \+                     \+               402 nmol/l      232 nmol/l    222      4.22   NA             \+   p.W601\*
  9    −                      \+               384.6 nmol/l    117 nmol/l    36.34    1.51   −              \+   NA
  10   −                      \+               470.90 nmol/l   102 nmol/l    211.00   3.27   −              NA   p.S149R

17-KS, 17-ketosteroids; 17-OH-CS, 17-hydroxycorticosteroids; CT, computed tomography; MRI T2WI, magnetic resonance imaging T2 weighted image; IC, internal capsule; Bs, brainstem; VLCFAs, very long chain fatty acids; C22:0, docosanoic acid; C24:0, tetracosanoic acid; C26:0, hexacosanoic acid; CSF, cerebrospinal fluid; EMG, electromyography; NCV, nerve conduction velocity; +, positive; -, negative; NA, not available. Bracketed numbers in the headings denote the normal range.

###### 

Treatment and follow-up of 10 patients with X-linked adrenoleukodystrophy.

  Case no.   Duration of follow-up (years)   Treatment                                                                                                 Outcome
  ---------- ------------------------------- --------------------------------------------------------------------------------------------------------- ----------------------
  1          15.3                            Anti-convulsants, penicillin, neurotrophic drugs, hormone replacement therapy, low-VLCFA diet, ATP, CoA   Addison only
  2          5.6                             Penicillin, neurotrophic drugs, hormone replacement therapy, ATP, CoA                                     Disability
  3          12.3                            Anti-convulsants, penicillin, neurotrophic drugs, hormone replacement therapy, low-VLCFA diet, ATP, CoA   Dementia
  4          12                              Neurotrophic drugs, hormone replacement therapy, ATP, CoA                                                 Dementia, disability
  5          16.1                            Penicillin, neurotrophic drugs, hormone replacement therapy, ATP, CoA                                     Addison only
  6          4.8                             Ceftriaxone, neurotrophic drugs, hormone replacement therapy, ATP                                         Dementia
  7          11.5                            Azithromycin, neurotrophic drugs, hormone replacement therapy, low-VLCFA diet                             Addison only
  8          2.4                             Neurotrophic drugs, hormone replacement therapy, ATP, HSCT                                                Death
  9          8.9                             No treatment                                                                                              Asymptomatic
  10         1.6                             Neurotrophic drugs, hormone replacement therapy                                                           Exacerbation

HSCT, hematopoietic stem cell transplantation; VLCFA, very long chain fatty acid.
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